1. Home
  2. CBIO vs AREN Comparison

CBIO vs AREN Comparison

Compare CBIO & AREN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CBIO
  • AREN
  • Stock Information
  • Founded
  • CBIO 2003
  • AREN 2016
  • Country
  • CBIO United States
  • AREN United States
  • Employees
  • CBIO N/A
  • AREN N/A
  • Industry
  • CBIO
  • AREN Medical/Dental Instruments
  • Sector
  • CBIO
  • AREN Health Care
  • Exchange
  • CBIO Nasdaq
  • AREN Nasdaq
  • Market Cap
  • CBIO 308.0M
  • AREN 305.8M
  • IPO Year
  • CBIO N/A
  • AREN N/A
  • Fundamental
  • Price
  • CBIO $14.29
  • AREN $5.90
  • Analyst Decision
  • CBIO Strong Buy
  • AREN Strong Buy
  • Analyst Count
  • CBIO 5
  • AREN 1
  • Target Price
  • CBIO $25.60
  • AREN $12.00
  • AVG Volume (30 Days)
  • CBIO 98.3K
  • AREN 243.8K
  • Earning Date
  • CBIO 07-31-2025
  • AREN 08-14-2025
  • Dividend Yield
  • CBIO N/A
  • AREN N/A
  • EPS Growth
  • CBIO N/A
  • AREN N/A
  • EPS
  • CBIO N/A
  • AREN 2.74
  • Revenue
  • CBIO N/A
  • AREN $146,610,000.00
  • Revenue This Year
  • CBIO N/A
  • AREN $29.48
  • Revenue Next Year
  • CBIO N/A
  • AREN $11.72
  • P/E Ratio
  • CBIO N/A
  • AREN $9.36
  • Revenue Growth
  • CBIO N/A
  • AREN 6.81
  • 52 Week Low
  • CBIO $10.83
  • AREN $0.56
  • 52 Week High
  • CBIO $21.40
  • AREN $10.05
  • Technical
  • Relative Strength Index (RSI)
  • CBIO 52.92
  • AREN 41.23
  • Support Level
  • CBIO $13.50
  • AREN $6.09
  • Resistance Level
  • CBIO $16.00
  • AREN $7.00
  • Average True Range (ATR)
  • CBIO 0.79
  • AREN 0.64
  • MACD
  • CBIO 0.16
  • AREN -0.12
  • Stochastic Oscillator
  • CBIO 39.68
  • AREN 1.52

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About AREN The Arena Group Holdings Inc.

The Arena Group Holdings Inc is a tech-powered media company that fuses technology, iconic brands, and marketing to deliver vibrant content and experiences that reach million users each month. The company creates robust digital destinations that delight consumers with powerful journalism, news about things such as favorite sports teams, advice on investing, the inside scoop on personal finance, and the latest on lifestyle essentials. The Company operates in one reportable segment which focuses on a publishing platform. The company generates revenue from Digital and Print, where the majority is generated from Digital. The company owns and operates TheStreet, The Spun, Parade, and Men's Journal and powers more than 320 independent Publisher Partners.

Share on Social Networks: